Global consumption of microbial therapeutic products is predicted to be worth USD 17.11 Billion in 2022. The market is projected to register 7.5% CAGR and reach a valuation of USD 30.55 Billion by the end of 2030.
| Attribute | Details |
|---|---|
| Microbial Therapeutic Products Market Size (2022) | USD 17.11 billion |
| Revenue Forecast (2030) | USD 30.55 billion |
| Global Market Growth Rate (2022 to 2030) | 7.5% CAGR |
| Dominant Application | Oncology (24.2% Share) |
The microbial therapeutic products market is expected to continue to rise at a healthy rate owing to rising incidence of antibiotic resistance across the world. Microbial therapeutic products currently account for 10.7% share in the global cancer therapy market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 7.47% |
| H1, 2022 Projected | 7.51% |
| H1, 2022 Outlook | 7.31% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 20 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 16 ↓ |
The market for microbial therapeutic products is subject to changes as per the regulatory impositions and quality control guidelines within its region of jurisdiction, with reference to the macro and industry scale dynamics.
H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 20 BPS. However, In H1-2022, the market growth rate of microbial therapeutic products is expected to fall by 16 basis point share (BPS), as per FMI analysis.
The drop in the BPS values observed is due to the initial restrictive impact of the COVID-19 pandemic globally. With the restrictions in production and distribution activities, the market observed a decline in the BPS values. Moreover, the high cost of production of microbial therapeutic products also poses operational cost burden upon manufacturers.
Conversely, with the growing trend of contract manufacturing within developing countries of the Asian region for microbial therapeutic products, the market is set to expand with a positive growth outlook over the forecasted years. The key developments in the market include the expansion of the bioprocess industry into processes with consolidated flow for up-scale of materials.
A microbe, such as a bacteria, yeast, or fungus, is a microscopic living entity. Microbes create microbial treatment products, which are mostly used to make cheese, wine, vinegar, and bread. Enzyme, antibiotic, and nutrition production are all examples of medicinal microbiology.
Microbes have been portrayed as our enemies throughout most of modern medical history; yet, it is now plainly obvious that they can be exploited as therapies. In reality, a growing number of firms currently are focusing on microbial treatment products leading to clinical development in their product pipelines. The few extant live bacterial prophylactic vaccines and more recent efforts employing fecal microbiota transplant demonstrate the potential of therapeutic microbial.
Several studies have found that microbial imbalance is linked to the risk of getting certain diseases. The commercial prospects have improved as the focus on creating therapeutic microbial medicines that treat and successfully mitigate the development of these kinds of diseases has gained traction.
The microbial therapeutic products market expanded at a CAGR of 6.6% from 2015 to 2021, and amassed revenue worth USD 15.94 Billion in 2021. The market is primarily driven by rising prevalence of lifestyle-related chronic diseases and antibiotic resistance.
As a result, market players are scrambling to create novel solutions and products to cure a variety of immunological illnesses and other bodily ailments, consequently expanding the market's scope in the coming years.
Sales of microbial therapeutic products are predicted to surge at a CAGR of 7.5% from 2022 to 2030, with the global market expected to close in on a valuation of USUSD 30.55 Billion by 2030.
Principal Consultant
Increasing Cases of Chronic Disorders Fueling Sales of Microbial Therapeutic Products
WHO reports that "Noncommunicable diseases (NCDs) claim the lives of 41 million people each year, accounting for 71% of all deaths worldwide. More than 15 million people between the ages of 30 and 69 die each year from an NCD; 85 percent of these "premature" deaths occur in low- and middle-income nations ".
Chronic diseases, also known as noncommunicable diseases, are long-term illnesses caused by a mix of genetic, physiological, environmental, and behavioural factors. Diabetes, cardiovascular disease, cancer, and asthma are all likely to become more common as the global senior population grows.
Pharmaceutical companies are boosting their research to produce viable therapies against this backdrop. The importance of microbes in human health and disease has become increasingly recognized over time.
By combining non-pathogenic bacteria into living biotherapeutics made up of synthetic microbes, a new study has revealed the possibilities of building live biotherapeutics to address specific disease pathways. Given the rising prevalence of the global population and the growth of numerous lifestyle disorders, emerging economies are anticipated to emerge as potential opportunity centers.
Improved Technologies in Disease Diagnostic Driving Demand for Microbial Therapeutic Solutions
Disease diagnosis is transforming as the global healthcare business faces paradigm transformations. Healthcare institutions are investing in technologically enhanced testing and diagnostic procedures in response to increased demand for shorter turnaround times, multiplexing of reactions, and specificity.
Clinical trials are currently underway to explore in-vivo techniques as well as other minimally invasive procedures to improve patient comfort.
Rising Investments in R&D of Biological Drugs Aiding Sales Microbial Therapeutic Solutions
Governments worldwide have proactively lobbied for increased funding allocation to even further biosimilar medication development research works. The FDA in the United States, for example, has recently approved roughly 300 biologics products, with 87 percent of them being imports.
This is expected to open up new opportunities for the development of future microbial therapeutic products. Europe, on a similar note, has favourable reimbursement regulations for drug development.
Based on these trends, the future of microbial therapeutic products appears to be bright, with major manufacturers striving to establish a consolidated presence across key regions throughout the projected period.
Dearth of Proper Data May Decrease Microbial Therapeutic Enzyme Demand
The scarcity of proper data is a serious challenge for microbial therapy professionals. According to Microbiotica, a famous microbiome researcher, the mapping of diverse bacteria sources is imprecise, making most treatments unnecessary. While identification is possible, the consequences of many strains on human health are unknown.
Furthermore, many of the specific bacteria's functions can be shared by unrelated species. Thus, there may only be one comparable strain within a group of roughly ten germs connected to any given disease. This provides a problem in terms of determining which formulations should be used to ensure the drug's efficacy.
Even though that a variety of treatment options have arisen, there is no universal agreement on which, is most effective. One such option is live bacterial therapies, which, despite being widely used, are still equivocal in terms of effectiveness. Many researchers have been unsuccessful in demonstrating how to live bacteria engraft and persist in the gut after intake.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Increasing Cases of Chronic Disorders Augmenting Sales Growth of North America Market
North America will continue to be the world's largest market for microbial therapeutics products, with global volume sales expected to rise at a rapid pace. The key growth catalyst is the increasing frequency of regulatory approvals for biosimilar candidates. Chronic disease cases are on the rise, which bodes well for market expansion.
According to the NCBI, cancer has been a serious public health concern in Europe since the beginning of the twenty-first century, with a prevalence rate of about 3% and rising to 15% as people get older. The main factor is the growing geriatric population.
Furthermore, the World Health Organization predicts that noncommunicable diseases such as diabetes, chronic respiratory diseases, mental disorders, and cardiovascular diseases (CVDs) account for 86 percent of fatalities and 77 percent of the disease burden in the region. This is partly due to the predominance of sedentary behaviours.
Furthermore, as bacteria strains evolve, the burden of contagious diseases is increasing, as is antibiotic resistance. As a result, pharmaceutical companies are rushing to create a variety of microbial therapeutic solutions.
By 2030, the East Asia market is predicted to grow at a dizzying rate. The growing presence of key pharmaceutical companies that are introducing novel drug combinations to address the rising burden of chronic and infectious diseases is largely to blame for the industry's growth.
Rising Cases of Cancer Increasing Demand for Microbial Therapeutic Products
The increased prevalence of cancer in the United States is expected to increase the demand for microbial therapeutic solutions. In the United States, cancer is the second largest cause of death.
"In 2022, there will be a predicted 1.9 Million new cancer cases diagnosed and 609,360 cancer deaths in the United States," according to cancer.org.
Pharmaceutical companies are utilizing microbial treatments, largely bacteria-derived, to regress various forms of cancer and other ailments as a result of this, prompting experts to create a variety of modified bacterial strains.
Presence of Key Pharma Companies Aiding Microbial Therapeutic Products Market Growth
One of the most potential biotechnologies in the globe is biopharmaceutical technology. Biopharmaceuticals are flourishing and increasing rapidly as a worldwide high-tech biotechnology business, providing biopharmaceuticals with unparalleled market possibilities in China and other developing countries, due to the advancement of modern biotechnology.
Growth of biopharmaceutical solutions in the country is increasing because most pharma and biopharma companies are focusing on capitalizing on the expansion, including looking for opportunities to collaborate/partner with local firms, which is assisting the emergence and growth of the microbial therapeutics products market over the forecast period.
Anti-cancer Agents Offer Plethora of Possibilities Due to Increasing R&D Investments by Key Producers
Growing worldwide cancer burden is fuelling rapid improvements in oncology, opening the door for increased anti-cancer drug sales in key regions. The segment is predicted to reach massive volume sales by 2022 end. For a variety of malignancies, a crucial growth stimulant, several precision-based therapy candidates are being investigated.
Simultaneously, demand for antimicrobial growth factors is increasing significantly. Healthcare and pharmaceutical key companies are incorporating this method into their medicine formulations due to the increased possibility for improved tissue regeneration among patients. Through 2030, the segment is expected to expand at a high CAGR.
Single-use Pre-filled Injections/Injector Pens to Remain Eminent Route of Administration
Single-use pre-filled injections will be the most commonly used technique for infusing microbial therapeutic agents by route of delivery. Concerns about infection transmission through multiple-use injections are driving an increase in the use of single-use injection pens.
The others segment is predicted to have the most influence, generating more than 40% of revenue over the forecast period. Eco Therapeutics and fecal microbiota transplants are becoming more common, especially when it comes to changing the gut microbiota.
Wide Availability of Bacteria-based Microbial Therapeutic Products in the Market
Bacterium-derived microbial therapeutic products are likely to remain profitable due to their widespread availability from various sources. Furthermore, microbes have served as the foundation for the development and manufacture of a variety of therapeutic medications, including antibiotics and vitamins.
Because of their benign nature, the gut microbiota has been a popular bacteria culturing source over time. Intestinal bacteria have proven to be quite beneficial in the treatment of digestive problems and food poisoning. As a result, genetic engineering strategies for extracting them have proliferated in recent years.
Oncology to Remain Key Application Area of Microbial Therapeutic Products
Despite significant improvements in cancer treatment, new therapeutic platforms are currently being studied to provide cancer patients with the best possible care. This increased search is projected to result in significant growth potential in the oncology market.
At present, oncology and metabolic disorders are likely to account for 24.2% and 20% of the global market share respectively. While infectious and allergic diseases together are likely to hold 18.8% of the global market share, in 2022.
Bacteriocin antibiotics, enzymes, and peptides, according to research, have a lot of potential for producing anti-cancer medications. Bacteriocins appear to be the most promising candidate for future medication development.
In 2022, haematological disorders and immunological disorders are expected to account for 12.6% and 9.6% of the global market share respectively. The other applications are predicted to hold 14.8% of the global market share currently.
Some of the market players featured in this report are Mylan N.V., F. Hoffmann La-Roche Ltd., Novartis AG, Amgen Inc., Merck & Co. Inc., Biocon, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Boehringer Ingelheim, Bristol-Myers Squibb Company, and Abbot Laboratories.
Pfizer Inc., Sanofi S.A., Merck & Co., Amgen Inc., and Novartis AG account for a majority of overall revenue. To commercialize and sell their products, these companies place strong emphasis on collaborative license agreements with other partners.
Furthermore, some market players are concentrating on acquisitions and the launch of biosimilars. Companies are also looking for more favourable regulatory approvals to get into profitable sectors.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2030 |
| Historical Data Available for | 2015 to 2021 |
| Market Analysis | USD Billion for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa and GCC Countries |
| Key Market Segments Covered | Product, Route of Administration, Source, Application, End User, Region |
| Key Companies Profiled | Mylan N.V.; F. Hoffmann La-Roche Ltd.; Novartis AG; Amgen Inc.; Merck & Co. Inc.; Biocon; Pfizer Inc.; Dr. Reddy’s Laboratories Ltd.; Intas Pharmaceuticals Ltd.; Novo Nordisk A/S; Eli Lilly and Company; Sanofi S.A.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Abbot Laboratories |
| Pricing | Available upon Request |
The global microbial therapeutic products market is estimated to progress at a high CAGR of 7.5% through 2030.
The microbial therapeutic products market report is segmented into product, route of application, source, application, end user, and region.
The global market for microbial therapeutic products is currently worth USD 17.11 Billion, and is anticipated to attain a valuation of USD 30.55 Billion by 2030.
In 2022, oncology is predicted to account for 24.2% of the global market share.
The North America market is expected to grow at a high rate, thereby being advantageous for microbial therapeutic product producers.
Due to ongoing research & development by top healthcare providers to find a robust treatment candidate for eradicating the current coronavirus outbreak, the COVID-19 pandemic has only contributed to driving the expansion of the microbial therapeutic products market.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Market Background 5. Market Context 6. Global Microbial Therapeutic Products Market Value (USD Million) Analysis 2015 to 2021 and Forecast, 2022 to 2030 7. Global Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030, By Product 7.1. Growth Factors 7.1.1. GCSF 7.1.2. PEG-GCSF 7.1.3. Exenatide 7.2. Anti-cancer Agents 7.3. Immuno-Suppressants 7.4. Enzymes 7.5. Others 8. Global Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030, By Route of Administration 8.1. Single Use Pre-Filled Injection/Route of Administration pen 8.2. Multi-use Route of Administrations 8.3. Others 9. Global Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030, By Source 9.1. Bacteria 9.2. Fungi 10. Global Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030, By Application 10.1. Metabolic Disorders 10.2. Hematological Disorders 10.3. Oncology 10.4. Immunology Disorders 10.5. Infectious Diseases 10.6. Allergic Disorders 10.7. Others 11. Global Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030, by End User 11.1. Hospitals 11.2. Pharmaceutical and Biopharmaceutical Companies 11.3. Research and Academic Institutes 12. Global Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030, by Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. East Asia 12.5. South Asia 12.6. Oceania 12.7. Middle East and Africa (MEA) 13. North America Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030 14. Latin America Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030 15. Europe Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030 16. East Asia Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030 17. South Asia Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030 18. Oceania Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030 19. Middle East and Africa Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030 20. Key and Emerging Countries Microbial Therapeutic Products Market Analysis 2015 to 2021 and Forecast 2022 to 2030 21. Market Structure Analysis 22. Competition Analysis 22.1. Mylan N.V. 22.2. F. Hoffmann-La Roche Ltd. 22.3. Novartis AG 22.4. Amgen Inc. 22.5. Merck & Co. Inc. 22.6. Biocon 22.7. Pfizer Inc. 22.8. Dr. Reddy’s Laboratories Ltd. 22.9. Intas Pharmaceuticals Ltd. 22.10. Novo Nordisk A/S 22.11. Eli Lilly and Company 22.12. Sanofi S.A. 22.13. Boehringer Ingelheim 22.14. Bristol-Myers Squibb Company 22.15. Abbott Laboratories 23. Assumptions and Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Microbial Therapeutic Products Market
